Melanotan-II — clinical evidence
Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.
§3Clinical evidence
§3.1Hypoactive sexual desire and erectile dysfunction
Anchor outcome. Female Sexual Function Index desire domain.
Effect as recorded. No adequately powered randomised trial identified for this compound; —.[1,2]
Certainty. Very low certainty Development was discontinued. The approved compound in this family is its metabolite bremelanotide, and evidence for that compound does not transfer.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for hypoactive sexual desire and erectile dysfunction · Indication assessment
§3.2Obesity and overweight in adults
Anchor outcome. Percentage change in body weight from baseline.
Effect as recorded. No randomised trial identified; —.[2,3]
Certainty. Very low certainty Appetite suppression is reported anecdotally and is mechanistically expected from MC4R agonism, but no trial exists.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for obesity and overweight in adults · Indication assessment
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health 2016;12(3):325–337. doi:10.2217/whe-2016-0018 · PMID 27638896
- Carvalho M, Dinis-Oliveira RJ. Analytical and forensic aspects of counterfeit peptide hormones. Drug Testing and Analysis 2023;15(1):5–19. doi:10.1002/dta.3379
- Medicines and Healthcare products Regulatory Agency. Falsified Ozempic (semaglutide) pens: patient safety alert. MHRA Safety Alert 2023;Alert reference NatPSA/2023/012/MHRA. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.